Trends in cell therapy industry clinical trials

by Alexey Bersenev on February 24, 2014 · 0 comments

in RegenMed digest

Post to Twitter Send Gmail Post to LinkedIn

As a part of a CellTrials project, I’m tracking all cell therapy clinical trials, registered in international databases. You can read more about the tracking project here and follow annual updates. I’m sharing some analysis every year in order to inform professionals and public about trends in the field. Today I’m going to share a piece of data, related to industry-sponsored clinical trials.

Total number of clinical trials
This graph represents total number of cell therapy clinical trials, registered in databases from 2011 to 2013 – academic versus industry:


As you can see from the graph, industry had about equal number of trials in 2011 and 2012, but last year it went up. It looks like cell therapy industry is taking off!

Allo- versus auto- business model
One may think (and speculate) that allogeneic (drugs-like) business model is more attractive for industry. But, based on clinical trials data, it may not be the case. Let’s look at this trend:


As you can see, there was no preference for allo- versus auto- business model among clinical stage cell therapy companies. Slight shift to auto- model in 2013 could be related to the boom of cellular immunotherapy in oncology.

RegenMed Industry Digest sponsored by:

{ 0 comments… add one now }

Leave a Comment

Previous post:

Next post: